Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Pharmaceutical Industry Roundup: M&A Surge, Leadership Changes, and Breakthrough Therapies

In a week of significant developments for the pharmaceutical industry, major acquisitions, leadership transitions, and promising clinical results have reshaped the landscape. From multibillion-dollar deals to potential breakthroughs in treating neurodegenerative diseases, the sector continues to evolve rapidly.

NoahAI News10/1/2025

Pharmaceutical Industry Update: FDA Approval, M&A Activity, and Clinical Trial Results

The U.S. Food and Drug Administration (FDA) has approved Novartis' Rhapsido (remibrutinib) for the treatment of chronic spontaneous urticaria, a form of persistent hives. This approval marks a significant milestone as Rhapsido becomes the first oral targeted therapy for this condition. The drug belongs to a newer class of BTK inhibitors designed to treat autoimmune diseases rather than cancer, following closely on the heels of Sanofi's Wayrilz, which received clearance for immune thrombocytopenia in late August.

NoahAI News10/1/2025

Irish Biotech Aerska Launches with $21M to Develop Brain-Targeted RNA Therapeutics

Aerska, a new biotechnology company headquartered in Dublin with research operations in London, has emerged on the pharmaceutical scene with a $21 million seed funding round. The company's mission is to revolutionize the delivery of genetic medicines to the brain, focusing initially on Alzheimer's and Parkinson's diseases.

NoahAI News10/1/2025

AbbVie Expands US Operations with $70M Investment in Massachusetts Facility

AbbVie, the Chicago-based pharmaceutical giant, has initiated a significant expansion of its bioresearch center in Worcester, Massachusetts, marking another milestone in its ambitious $10 billion US investment strategy. The $70 million project, announced on September 30, 2025, aims to enhance the company's biologics manufacturing capabilities and accelerate the production of oncology and immunology drugs.

NoahAI News10/1/2025

Q3 Biopharma Acquisitions Surge with High-Value Deals

The third quarter of 2025 has witnessed a significant uptick in high-value biopharma acquisitions, marking a potential shift in industry sentiment towards larger transactions. While Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular in January remains the top deal of the year, the past four months have seen a flurry of major acquisitions reshaping the pharmaceutical landscape.

NoahAI News10/1/2025

Big Pharma's M&A Firepower: Industry Giants Poised for Strategic Acquisitions

In a landscape of evolving healthcare needs and fierce competition, the pharmaceutical industry's top players are sitting on a substantial war chest for mergers and acquisitions. A recent analysis by Stifel reveals that the 18 largest pharmaceutical companies have a combined $1.2 trillion in "stretch firepower" available for M&A activities, with $500 billion considered "comfortable firepower."

NoahAI News10/1/2025

Life Sciences M&A Milestone Payments Fall Short of Expectations, New Analysis Reveals

In a revealing analysis of life sciences mergers and acquisitions (M&A), SRS Acquiom has shed light on the stark reality of milestone payments in the industry. The report, which examined 342 deals signed between 2008 and 2025, found that only 9.5% of potential earnouts have been paid, highlighting the risks and challenges faced by biotechnology companies in back-loaded deals.

NoahAI News10/1/2025

Kyorin Pharmaceutical Secures $105M Deal for Hinge Bio's Lupus Drug in Japan

Kyorin Pharmaceutical has made a significant move to bolster its autoimmune portfolio by acquiring the Japanese rights to Hinge Bio's preclinical lupus drug, HB2198. The deal, valued at up to $105 million, marks a substantial investment in the emerging field of B-cell depletion therapies for autoimmune disorders.

NoahAI News10/1/2025

Sutro Biopharma Announces Second Major Restructuring in 2025

Sutro Biopharma, a San Francisco-based biopharmaceutical company, has announced a significant restructuring effort aimed at extending its financial runway and focusing resources on key pipeline programs. This marks the second major workforce reduction for the company in 2025, following a previous cut of 50% of its employees earlier this year.

NoahAI News10/1/2025

Pfizer's $4.9B Bet on Metsera's Obesity Drug Shows Promise in Mid-Stage Trial

Pfizer's recent $4.9 billion acquisition of Metsera appears to be paying off, as the biotech's investigational long-acting GLP-1 therapy, MET-097i, demonstrates encouraging efficacy in a mid-stage clinical trial. The drug's performance in weight reduction and tolerability profile positions it as a potential competitor to established obesity treatments, supporting Pfizer's strategic move in the rapidly growing market for weight loss medications.

NoahAI News10/1/2025

Biopharma Layoffs Surge in 2025 Amid Strategic Shifts and Economic Pressures

Pharmaceutical Industry News Roundup: Layoffs and Restructuring Sweep SectorIn a wave of strategic realignments and cost-cutting measures, numerous pharmaceutical and biotech companies have announced significant workforce reductions and organizational changes in recent months. This industry-wide trend reflects ongoing challenges in drug development, shifting market dynamics, and efforts to streamline operations amid economic pressures.

NoahAI News10/1/2025

Virtual Women's Health Clinic Visana Health Secures $24M in Series A Funding

Visana Health, a virtual women's health clinic focused on complex patients, has successfully closed a $24 million series A funding round. The investment, led by Noro-Moseley Partners with support from Cigna Group Ventures and Intermountain Ventures, aims to expand the company's clinical offerings and enhance its technological infrastructure.

NoahAI News10/1/2025

«1...39 40 41...67 »